S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
pixel
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
pixel
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
pixel
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
pixel
Log in
NASDAQ:ARLZ

Aralez Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.03
0.00 (0.00 %)
(As of 08/21/2018)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.03
50-Day Range N/A
52-Week Range
$0.02
Now: $0.03
$2.98
VolumeN/A
Average Volume5.13 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.
Aralez Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ARLZ
CUSIP73941U10
Phone905-876-1118
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1561st out of 1,958 stocks

Pharmaceutical Preparations Industry

670th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive ARLZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARLZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aralez Pharmaceuticals (NASDAQ:ARLZ) Frequently Asked Questions

What stocks does MarketBeat like better than Aralez Pharmaceuticals?

Wall Street analysts have given Aralez Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aralez Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) posted its earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. The company had revenue of $24.30 million for the quarter, compared to analyst estimates of $22.87 million. The business's quarterly revenue was up 78.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.32) EPS.
View Aralez Pharmaceuticals' earnings history
.

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the following people:
  • Mr. Adrian Adams, CEO & Director (Age 67)
  • Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
  • Mr. Michael Kaseta, Chief Financial Officer (Age 42)
  • Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
  • Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)

Who are some of Aralez Pharmaceuticals' key competitors?

What other stocks do shareholders of Aralez Pharmaceuticals own?

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

What is Aralez Pharmaceuticals' stock price today?

One share of ARLZ stock can currently be purchased for approximately $0.03.

What is Aralez Pharmaceuticals' official website?

The official website for Aralez Pharmaceuticals is www.aralez.com.

Where are Aralez Pharmaceuticals' headquarters?

Aralez Pharmaceuticals is headquartered at 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.